Literature DB >> 7942542

Elevation of the creatine kinase myocardial isoform following otherwise successful directional coronary atherectomy and stenting.

A D Kugelmass1, D J Cohen, M Moscucci, R N Piana, C Senerchia, R E Kuntz, D S Baim.   

Abstract

Moderate elevation of creatine kinase (CK) MB isoform is common following otherwise successful percutaneous coronary revascularization, and is frequently interpreted as evidence of a non-Q-wave myocardial infarction. It is not clear, however, whether elevation of CK MB isoform carries sufficient adverse clinical impact to be categorized as a "major" complication. We therefore explored the incidence and clinical consequence of elevation of CK MB isoform in a consecutive series of 565 patients who had otherwise successful directional coronary atherectomy (n = 274) or stenting (n = 291), and were followed for a mean of 2 years. Of this cohort, 11.5% had postprocedure elevation of the CK MB isoform above normal (10 IU/liter). These patients tended to be older and to have undergone atherectomy of a de novo lesion with adverse morphology (thrombus, calcification, eccentricity). Patients with elevation of CK MB isoform following otherwise successful revascularization generally showed no adverse long-term sequelae (death, recurrent myocardial infarction, repeat revascularization) compared with patients without elevation of CK MB isoform. Only 2.3% of the patients who had CK MB isoform release > 50 IU/liter demonstrated a trend (p = 0.08) toward decreased late survival, compared with patients without CK MB isoform elevation. While minor CK MB isoform elevation is common (11.5%) after successful coronary stenting or directional atherectomy, it generally has no adverse clinical consequences, and should not be considered a major complication.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7942542     DOI: 10.1016/0002-9149(94)90427-8

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trial.

Authors:  Stefanie Schulz; Julinda Mehilli; Gjin Ndrepepa; Franz Dotzer; Michael Dommasch; Sebastian Kufner; Kathrin A Birkmeier; Klaus Tiroch; Robert A Byrne; Albert Schömig; Adnan Kastrati
Journal:  Clin Res Cardiol       Date:  2011-03-08       Impact factor: 5.460

2.  Validity of Cardiac Markers as Diagnostic and Prognostic Indicators of Complications in Patients undergoing Percutaneous Coronary Intervention.

Authors:  Hafidh A Alhadi; Keith A A Fox
Journal:  Sultan Qaboos Univ Med J       Date:  2010-04-17

3.  Clinical events following excimer laser angioplasty or balloon angioplasty for complex coronary lesions: subanalysis of a randomised trial.

Authors:  Y E Appelman; J J Piek; W K Redekop; P J de Feyter; J J Koolen; G K David; S Strikwerda; J G Tijssen; P W Serruys; E van Swijndregt; M J van Gemert; K I Lie
Journal:  Heart       Date:  1998-01       Impact factor: 5.994

4.  Pharmacological prevention of peri-, and post-procedural myocardial injury in percutaneous coronary intervention.

Authors:  Hideki Ishii; Tetsuya Amano; Tatsuaki Matsubara; Toyoaki Murohara
Journal:  Curr Cardiol Rev       Date:  2008-08

Review 5.  Use of clopidogrel in the reduction of myocardial damage during percutaneous coronary intervention.

Authors:  Arijit Dasgupta; Debabrata Mukherjee
Journal:  Vasc Health Risk Manag       Date:  2009-04-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.